Produktinformation
- (2β,9β,10α,16α,23E)-25-(Acetyloxy)-2,16,20-trihydroxy-9-(hydroxymethyl)-19-norlanosta-5,23-diene-3,11,22-trione
- 19-Nor-9β,10α-lanosta-5,23-diene-3,11,22-trione, 2β,16α,20,25-tetrahydroxy-9-(hydroxymethyl)-, 25-acetate, (E)-
- 19-Norlanosta-5,23-diene-3,11,22-trione, 2,16,20,25-tetrahydroxy-9-(hydroxymethyl)-, 25-acetate
- 19-Norlanosta-5,23-diene-3,11,22-trione, 25-(acetyloxy)-2,16,20-trihydroxy-9-(hydroxymethyl)-, (2.beta.,9.beta.,10.alpha.,16.alpha.,23E)-
- 19-Norlanosta-5,23-diene-3,11,22-trione, 25-(acetyloxy)-2,16,20-trihydroxy-9-(hydroxymethyl)-, (2β,9β,10α,16α,23E)-
- Cucurbitacine A
- NSC 94743
Cucurbitacin A is a polyphenolic secondary metabolite that has been shown to have a variety of biological activities. It has been shown to inhibit HIV-1 replication and induce apoptosis in cancer cells. Cucurbitacin A also inhibits the growth of human prostate cancer cells by inhibiting the expression of proteins involved in cell proliferation, such as cyclin D1 and p27. Cucurbitacin A also has potent anticancer activity against a broad range of cancer cells including breast, lung, colon, leukemia, melanoma, and ovarian cancers. Moreover, cucurbitacin A shows promise for the treatment of heart disease because it has been shown to inhibit platelet aggregation. The chemical stability and chemical composition make cucurbitacin A an attractive candidate for use as a pharmaceutical preparation.
Chemische Eigenschaften
Technische Anfrage zu: 3D-GAA04019 Cucurbitacin A
Wenn Sie ein Angebot anfordern oder eine Bestellung aufgeben möchten, legen Sie stattdessen die gewünschten Produkte in Ihren Warenkorb und fordern Sie dann ein Angebot oder eine Bestellung an aus dem Warenkorb. Es ist schneller, billiger und Sie können von den verfügbaren Rabatten und anderen Vorteilen profitieren.